Research programme: mucopolysaccharidoses I therapeutics - MiNA Therapeutics
Latest Information Update: 16 Aug 2023
At a glance
- Originator MiNA Therapeutics
- Class Oligonucleotides; RNA
- Mechanism of Action Iduronidase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Mucopolysaccharidosis I
Most Recent Events
- 01 Aug 2023 Research programme: mucopolysaccharidoses I therapeutics - MiNA Therapeutics is available for licensing as of 01 Aug 2023. https://minatx.com/ (MiNA Therapeutics website, January 2023)
- 21 Jul 2023 Early research in Mucopolysaccharidosis I in United Kingdom (Parenteral) (MiNA Therapeutics pipeline; July 2023)
- 01 Jan 2020 MiNA Therapeutics has patent protection for saRNA technology platform in USA granted before January 2020 (MiNA Therapeutics website, January 2023)